Metformin inhibits monocyte- To-macrophage differentiation via AMPK-mediated inhibition of STAT3 activation: Potential role in atherosclerosis

Diabetes

Volumn 64, Issue 6, 2015, Pages 2028-2041

  Vasamsetti, Sathish Babu ^a   Karnewar, Santosh ^a   Kanugula, Anantha Koteswararao ^a   Thatipalli, Avinash Raj ^b   Kumar, Jerald Mahesh ^b   Kotamraju, Srigiridhar ^a  

^a INDIAN INSTITUTE OF CHEMICAL TECHNOLOGY   (India)

^b CENTRE FOR CELLULAR AND MOLECULAR BIOLOGY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN II; APOLIPOPROTEIN E; GELATINASE A; GELATINASE B; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INTERLEUKIN 1BETA; INTERSTITIAL COLLAGENASE; LIPOPROTEIN LIPASE; METFORMIN; MONOCYTE CHEMOTACTIC PROTEIN 1; PHORBOL 13 ACETATE 12 MYRISTATE; STAT3 PROTEIN; STRESS ACTIVATED PROTEIN KINASE; TUMOR NECROSIS FACTOR ALPHA; POLYMETHACRYLIC ACID DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA ANEURYSM; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CELL DIFFERENTIATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOWN REGULATION; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; INFLAMMATION; MACROPHAGE; MALE; MOLECULAR PATHOLOGY; MONOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REGULATORY MECHANISM; UPREGULATION; ANIMAL; CYTOLOGY; DEFICIENCY; DRUG EFFECTS; GENETICS; KNOCKOUT MOUSE; METABOLISM;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; APOLIPOPROTEINS E; ATHEROSCLEROSIS; CELL DIFFERENTIATION; MACROPHAGES; MALE; METFORMIN; MICE; MICE, KNOCKOUT; MONOCYTES; POLYMETHACRYLIC ACIDS; STAT3 TRANSCRIPTION FACTOR;

EID: 84930762844     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db14-1225     Document Type: Article

References (30)

1. Hansson GK, Libby P. The immune response in atherosclerosis: A doubleedged sword. Nat Rev Immunol 2006;6:508-519.
2. Moore KJ, Tabas I. Macrophages in the pathogenesis of atherosclerosis. Cell 2011;145:341-355.
3. Li AC, Glass CK. The macrophage foam cell as a target for therapeutic intervention. Nat Med 2002;8:1235-1242.
4. Abbasi F, Chu JW, McLaughlin T, Lamendola C, Leary ET, Reaven GM. Effect of metformin treatment on multiple cardiovascular disease risk factors in patients with type 2 diabetes mellitus. Metabolism 2004;53:159-164.
5. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensiv e bloodglucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-865.
6. Matsumoto K, Sera Y, Abe Y, Tominaga T, Yeki Y, Miyake S. Metformin attenuates progression of carotid arterial wall thickness in patients with type 2 diabetes. Diabetes Res Clin Pract 2004;64:225-228.
7. Zhou G, Myers R, Li Y, et al. Role of AMP- Activated protein kinase in mechanism of metformin action. J Clin Invest 2001;108:1167-1174.
8. Zang M, Zuccollo A, Hou X, et al. AMP- Activated protein kinase is required for the lipid-lowering effect of metformin in insulin-resistant human HepG2 cells. J Biol Chem 2004;279:47898-47905.
9. Kahn BB, Alquier T, Carling D, Hardie DG. AMP- Activated protein kinase: Ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab 2005;1:15-25.
10. Hardie DG, Ross FA, Hawley SA. AMPK: A nutrient and energy sensor that maintains energy homeostasis. Nat Rev Mol Cell Biol 2012;13:251-262.
11. Lee WJ, Lee IK, Kim HS, et al. Alpha-lipoic acid prevents endothelial dysfunction in obese rats via activation of AMP- Activated protein kinase. Arterioscler Thromb Vasc Biol 2005;25:2488-2494.
12. Wu Y, Song P, Xu J, Zhang M, Zou MH. Activation of protein phosphatase 2A by palmitate inhibits AMP- Activated protein kinase. J Biol Chem 2007;282:9777-9788.
13. Yang Z, Kahn BB, Shi H, Xue BZ. Macrophage alpha1 AMP- Activated protein kinase (alpha1AMPK) antagonizes fatty acid-induced inflammation through SIRT1. J Biol Chem 2010;285:19051-19059.
14. Sag D, Carling D, Stout RD, Suttles J. Adenosine 59-monophosphate- Activated protein kinase promotes macrophage polarization to an anti-inflammatory functional phenotype. J Immunol 2008;181:8633-8641.
15. Yu W, Liu-Bryan R, Stevens S, Damanahalli JK, Terkeltaub R. RAGE signaling mediates post-injury arterial neointima formation by suppression of liver kinase B1 and AMPK activity. Atherosclerosis 2012;222:417-425.
16. Daugherty A, Manning MW, Cassis LA. Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E-deficient mice. J Clin Invest 2000;105:1605-1612.
17. Gavrila D, Li WG, McCormick ML, et al. Vitamin E inhibits abdominal aortic aneurysm formation in angiotensin II-infused apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2005;25:1671-1677.
18. Gopal K, Nagarajan P, Jedy J, et al. b-Carotene attenuates angiotensin II-induced aortic aneurysm by alleviating macrophage recruitment in Apoe-/- mice. PLoS One 2013;8:e67098.
19. Sakamoto H, Aikawa M, Hill CC, et al. Biomechanical strain induces class a scavenger receptor expression in human monocyte/macrophages and THP-1 cells: A potential mechanism of increased atherosclerosis in hypertension. Circulation 2001;104:109-114.
20. Tontonoz P, Nagy L, Alvarez JG, Thomazy VA, Evans RM. PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell 1998;93:241-252.
21. Namgaladze D, Kemmerer M, von Knethen A, Brüne B. AICAR inhibits PPARg during monocyte differentiation to attenuate inflammatory responses to atherogenic lipids. Cardiovasc Res 2013;98:479-487.
22. Tiwari RL, Singh V, Singh A, Barthwal MK. IL-1R- Associated kinase-1 mediates protein kinase Cd-induced IL-1b production in monocytes. J Immunol 2011;187:2632-2645.
23. McLemore ML, Grewal S, Liu F, et al. STAT-3 activation is required for normal G-CSF-dependent proliferation and granulocytic differentiation. Immunity 2001;14:193-204.
24. Nerstedt A, Johansson A, Andersson CX, Cansby E, Smith U, Mahlapuu M. AMP- Activated protein kinase inhibits IL-6-stimulated inflammatory response in human liver cells by suppressing phosphorylation of signal transducer and activator of transcription 3 (STAT3). Diabetologia 2010;53: 2406-2416.
25. Lindholm CR, Ertel RL, Bauwens JD, Schmuck EG, Mulligan JD, Saupe KW. A high-fat diet decreases AMPK activity in multiple tissues in the absence of hyperglycemia or systemic inflammation in rats. J Physiol Biochem 2013;69: 165-175.
26. Steinberg GR, Kemp BE. AMPK in health and disease. Physiol Rev 2009;89: 1025-1078.
27. Li Y, Xu S, Jiang B, Cohen RA, Zang M. Activation of sterol regulatory element binding protein and NLRP3 inflammasome in atherosclerotic lesion development in diabetic pigs. PLoS One 2013;8:e67532.
28. Woo SL, Xu H, Li H, et al. Metformin ameliorates hepatic steatosis and inflammation without altering adipose phenotype in diet-induced obesity. PLoS One 2014;9:e91111.
29. Mullugeta Y, Chawla R, Kebede T, Worku Y. Dyslipidemia associated with poor glycemic control in type 2 diabetes mellitus and the protective effect of metformin supplementation. Indian J Clin Biochem 2012;27: 363-369.
30. Musi N, Hirshman MF, Nygren J, et al. Metformin increases AMP- Activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes. Diabetes 2002;51:2074-2081.